IGC Pharma (IGC) Revenue (2010 - 2025)

IGC Pharma (IGC) has reported Revenue for 16 consecutive years, with $191000.0 the latest figure, recorded in Q3 2025.

• On a quarterly basis, Revenue fell 53.64% year-over-year to $191000.0 in Q3 2025; TTM through Sep 2025 was $1.4 million, a 21.39% increase from a year earlier, with the FY2026 full-year figure at $317000.0, down 75.06% from the prior year.
• Revenue was $191000.0 for Q3 2025 at IGC Pharma, down from $658000.0 in the prior quarter.
• Over five years, Revenue peaked at $658000.0 in Q2 2025 and troughed at $56000.0 in Q3 2021.
• A 5-year average of $255526.3 and a median of $212000.0 in 2022 frame the typical range for Revenue.
• Across the five-year window, Revenue sank 86.82% in 2021 and surged 260.71% in 2022, its largest moves.
• Over 5 years, Revenue stood at $142000.0 in 2021, then jumped by 133.8% to $332000.0 in 2022, then slumped by 38.55% to $204000.0 in 2023, then grew by 25.98% to $257000.0 in 2024, then decreased by 25.68% to $191000.0 in 2025.
• The last three Revenue figures came in at $191000.0 (Q3 2025), $658000.0 (Q2 2025), and $330000.0 (Q1 2025), per Business Quant data.